

1. Sales January to September 2006 and 2005

January – September	2006	2005	% change	
	CHF m	CHF m	In CHF	In local currencies
Pharmaceuticals Division	23,912	19,434	+23	+21
Roche Pharmaceuticals	14,921	12,169	+23	+20
Genentech	6,522	4,632	+41	+37
Chugai	2,469	2,633	-6	-2
Diagnostics Division	6,415	6,008	+7	+5
Roche Group	30,327	25,442	+19	+17

2. Quarterly local sales growth by Division in 2005 and 2006

	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005
Pharmaceuticals Division	+34	+19	+19	+25
Roche Pharmaceuticals	+32	+19	+15	+25
Genentech	+49	+40	+39	+33
Chugai	+22	-8	+1	+2
Diagnostics Division	+3	+3	+5	+6
Roche Group	+26	+15	+16	+20

3. Quarterly sales by Division in 2005 and 2006

CHF millions	Q3 2005	Q4 2005	Q1 2006	Q2 2006	Q3 2006
Pharmaceuticals Division	6,782	7,834	7,739	7,838	8,335
Roche Pharmaceuticals	4,191	4,786	4,821	4,849	5,251
Genentech	1,765	1,982	2,056	2,167	2,299
Chugai	826	1,066	862	822	785
Diagnostics Division	2,038	2,235	2,091	2,181	2,143
Roche Group	8,820	10,069	9,830	10,019	10,478

4. Top 20 Pharmaceuticals Division product sales¹ and local growth² in YTD September 2006: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	3,525	15%	1,959	11%	138	2%	1,428	23%
Herceptin	2,822	92%	1,149	83%	110	31%	1,563	105%
Avastin	2,130	90%	1,582	62%	-	-	548	276%
NeoRecormon/Epogin	1,635	0%	-	-	489	-12%	1,146	6%
Tamiflu	1,630	88%	637	239%	236	-7%	757	81%
CellCept	1,357	7%	677	14%	23	18%	657	0%
Pegasys	1,074	2%	325	-11%	47	-24%	702	12%
Xeloda	711	22%	272	24%	20	-4%	419	23%
Tarceva	578	130%	372	55%	-	-	206	1607%
Xenical	523	7%	87	15%	-	-	436	6%
Xolair	392	34%	392	34%	-	-	-	-
Kytril	381	4%	156	3%	99	6%	126	3%
Nutropin	362	1%	352	1%	-	-	10	6%
Cymevene/Valcyte	349	20%	182	23%	-	-	167	16%
Pulmozyme	320	9%	184	6%	-	-	136	12%
Rocephin	312	-60%	23	-95%	42	0%	247	-14%
Bonviva/Boniva	309	768%	269	667%	-	-	40	-
Neutrogen	279	10%	-	-	279	10%	-	-
Activase/TNKase	267	16%	234	15%	-	-	33	17%
Dilatrend	234	-6%	-	-	-	-	234	-6%
New products not covered in Top 20								
Fuzeon	221	22%	108	18%	-	-	113	25%
Lucentis	205	-	205	-	-	-	-	-
Copegus	170	-48%	18	-88%	-	-	152	-12%
Evista	101	54%	-	-	101	54%	-	-
Raptiva	94	6%	94	6%	-	-	-	-
Renagel	46	19%	-	-	46	19%	-	-
Actemra	3	657%	-	-	3	657%	-	-
Femara	2	-	-	-	2	-	-	-

¹ Roche Pharmaceuticals, Genentech and Chugai combined ² versus YTD September 2005

5. Top 20 Pharmaceuticals Division quarterly local product sales growth¹ in 2005 and 2006

	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005
MabThera/Rituxan	23%	16%	16%	13%
Herceptin	77%	107%	103%	72%
Avastin	127%	141%	102%	55%
NeoRecormon/Epogin	12%	3%	0%	-4%
Tamiflu	631%	37%	133%	141%
CellCept	25%	15%	-1%	7%
Pegasys	17%	2%	3%	1%
Xeloda	47%	35%	21%	13%
Tarceva	722%	182%	119%	110%
Xenical	9%	16%	8%	-1%
Xolair	57%	39%	30%	34%
Kytril	5%	18%	-4%	0%
Nutropin	4%	-3%	1%	5%
Cymevene/Valcyte	23%	21%	12%	26%
Pulmozyme	15%	14%	4%	8%
Rocephin	-55%	-69%	-63%	-35%
Bonviva/Boniva	-	-	323%	929%
Neutrogen	18%	19%	12%	1%
Activase/TNKase	23%	19%	21%	9%
Dilatrend	3%	-6%	-8%	-4%

¹ Roche Pharmaceuticals, Genentech and Chugai combined

6. Pharmaceuticals Division quarterly local product sales growth¹ US in 2005 and 2006

	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005
MabThera/Rituxan	20%	7%	16%	9%
Herceptin	99%	123%	110%	40%
Avastin	88%	96%	72%	34%
NeoRecormon/Epogin	-	-	-	-
Tamiflu	390%	414%	143%	229%
CellCept	44%	32%	6%	9%
Pegasys	14%	-14%	-10%	-11%
Xeloda	64%	40%	24%	11%
Tarceva	528%	95%	46%	37%
Xenical	18%	24%	15%	6%
Xolair	57%	39%	30%	34%
Kytril	-2%	31%	-20%	5%
Nutropin	4%	-3%	1%	5%
Cymevene/Valcyte	14%	15%	20%	32%
Pulmozyme	15%	12%	0%	7%
Rocephin	-81%	-96%	-96%	-89%
Bonviva/Boniva	-	-	262%	818%
Neutrogen	-	-	-	-
Activase/TNKase	25%	19%	19%	9%
Dilatrend	-	-	-	-

¹ Roche Pharmaceuticals and Genentech combined

7. Pharmaceuticals Division quarterly local product sales growth Japan¹ in 2005 and 2006

	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005
MabThera/Rituxan	5%	3%	-1%	3%
Herceptin	26%	31%	30%	33%
Avastin	-	-	-	-
NeoRecormon/Epogin	7%	-3%	-9%	-22%
Tamiflu	733%	-33%	367%	6485%
CellCept	22%	15%	20%	19%
Pegasys	3%	-11%	-24%	-34%
Xeloda	20%	1%	-5%	-9%
Tarceva	-	-	-	-
Xenical	-	-	-	-
Xolair	-	-	-	-
Kytril	11%	6%	9%	4%
Nutropin	-	-	-	-
Cymevene/Valcyte	-	-	-	-
Pulmozyme	-	-	-	-
Rocephin	14%	-11%	8%	2%
Bonviva/Boniva	-	-	-	-
Neutrogen	18%	19%	12%	1%
Activase/TNKase	-	-	-	-
Dilatrend	-	-	-	-

¹ Chugai

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World¹ in 2005 and 2006

	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005
MabThera/Rituxan	32%	30%	20%	20%
Herceptin	69%	105%	107%	104%
Avastin	1203%	654%	294%	162%
NeoRecormon/Epogin	16%	6%	5%	6%
Tamiflu	864%	88%	124%	49%
CellCept	9%	2%	-7%	4%
Pegasys	23%	12%	13%	11%
Xeloda	37%	34%	20%	16%
Tarceva	-	-	2566%	867%
Xenical	7%	14%	7%	-3%
Xolair	-	-	-	-
Kytril	9%	13%	4%	-9%
Nutropin	-5%	12%	-4%	10%
Cymevene/Valcyte	36%	27%	5%	19%
Pulmozyme	16%	18%	10%	10%
Rocephin	-10%	-24%	-9%	-8%
Bonviva/Boniva	-	-	-	-
Neutrogin	-	-	-	-
Activase/TNKase	6%	14%	33%	7%
Dilatrend	3%	-6%	-8%	-4%

¹ Roche Pharmaceuticals

9. Top Pharmaceuticals Division quarterly product sales¹ in 2005 and 2006

CHF millions	Q3 2005	Q4 2005	Q1 2006	Q2 2006	Q3 2006
MabThera/Rituxan	1,057	1,153	1,146	1,202	1,177
Herceptin	591	704	861	952	1,009
Avastin	486	572	676	713	741
NeoRecormon/Epogin	564	602	535	565	535
Tamiflu	279	699	601	360	669
CellCept	441	464	454	437	466
Pegasys	350	373	350	374	350
Xeloda	213	228	238	234	239
Tarceva	101	141	172	195	211
Xenical	162	161	181	182	160
Xolair	104	123	124	133	135
Kytril	130	135	130	124	127
Nutropin	116	128	118	126	118
Cymevene/Valcyte	100	109	110	113	126
Pulmozyme	100	107	109	103	108
Rocephin	152	161	110	106	96
Bonviva/Boniva	14	51	75	92	142
Neutrogen	97	98	93	95	91
Activase/TNKase	84	87	88	90	89
Dilatrend	79	80	81	78	75
New products not covered in Top 20					
Fuzeon	62	81	72	71	78
Lucentis	-	-	-	13	192
Copegus	107	87	60	57	53
Evista	28	35	27	37	37
Raptiva	28	30	31	31	32
Renagel	15	16	13	16	17
Actemra	-	1	1	1	1
Femara	-	-	-	1	1

¹ Roche Pharmaceuticals, Genentech and Chugai combined

10. Pharmaceuticals Division quarterly product sales¹ in US in 2005 and 2006

CHF millions	Q3 2005	Q4 2005	Q1 2006	Q2 2006	Q3 2006
MabThera/Rituxan	612	672	634	675	650
Herceptin	271	321	375	400	374
Avastin	409	462	516	527	539
NeoRecormon/Epogin	-	-	-	-	-
Tamiflu	109	210	168	108	361
CellCept	225	244	221	215	241
Pegasys	124	137	103	115	107
Xeloda	83	99	92	90	90
Tarceva	92	108	120	129	123
Xenical	24	26	34	28	25
Xolair	104	123	124	133	135
Kytril	54	56	57	43	56
Nutropin	113	124	114	123	115
Cymevene/Valcyte	53	57	55	59	68
Pulmozyme	60	63	64	58	62
Rocephin	54	48	9	8	6
Bonviva/Boniva	13	48	69	78	122
Neutrogen	-	-	-	-	-
Activase/TNKase	73	77	78	78	78
Dilatrend	-	-	-	-	-
New products not covered in Top 20					
Fuzeon	34	44	33	36	39
Lucentis	-	-	-	13	192
Copegus	53	35	6	6	6
Evista	-	-	-	-	-
Raptiva	28	30	31	31	32
Renagel	-	-	-	-	-
Actemra	-	-	-	-	-
Femara	-	-	-	-	-

¹ Roche Pharmaceuticals and Genentech combined

11. Pharmaceuticals Division quarterly product sales¹ in Japan in 2005 and 2006

CHF millions	Q3 2005	Q4 2005	Q1 2006	Q2 2006	Q2 2006
MabThera/Rituxan	50	59	41	48	49
Herceptin	32	38	32	38	40
Avastin	-	-	-	-	-
NeoRecormon/Epogin	203	232	160	182	147
Tamiflu	2	133	170	9	57
CellCept	7	9	7	8	8
Pegasys	23	25	17	16	14
Xeloda	8	8	6	7	7
Tarceva	-	-	-	-	-
Xenical	-	-	-	-	-
Xolair	-	-	-	-	-
Kytril	35	40	29	36	34
Nutropin	-	-	-	-	-
Cymevene/Valcyte	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Rocephin	14	17	13	16	13
Bonviva/Boniva	-	-	-	-	-
Neutrogen	97	98	93	95	91
Activase/TNKase	-	-	-	-	-
Dilatrend	-	-	-	-	-
New products not covered in Top 20					
Fuzeon	-	-	-	-	-
Lucentis	-	-	-	-	-
Copegus	-	-	-	-	-
Evista	28	35	27	37	37
Raptiva	-	-	-	-	-
Renagel	15	16	13	16	17
Actemra	-	1	1	1	1
Femara	-	-	-	1	1

¹ Chugai

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World¹ in 2005 and 2006

CHF millions	Q3 2005	Q4 2005	Q1 2006	Q2 2006	Q3 2006
MabThera/Rituxan	395	422	471	479	478
Herceptin	288	345	454	514	595
Avastin	77	110	160	186	202
NeoRecormon/Epogin	361	370	375	383	388
Tamiflu	168	356	263	243	251
CellCept	209	211	226	214	217
Pegasys	203	211	230	243	229
Xeloda	122	121	140	137	142
Tarceva	9	33	52	66	88
Xenical	138	135	147	154	135
Xolair	-	-	-	-	-
Kytril	41	39	44	45	37
Nutropin	3	4	4	3	3
Cymevene/Valcyte	47	52	55	54	58
Pulmozyme	40	44	45	45	46
Rocephin	84	96	88	82	77
Bonviva/Boniva	1	3	6	14	20
Neutrogen	-	-	-	-	-
Activase/TNKase	11	10	10	12	11
Dilatrend	79	80	81	78	75
New products not covered in Top 20					
Fuzeon	28	37	39	35	39
Lucentis	-	-	-	-	-
Copegus	54	52	54	51	47
Evista	-	-	-	-	-
Raptiva	-	-	-	-	-
Renagel	-	-	-	-	-
Actemra	-	-	-	-	-
Femara	-	-	-	-	-

¹ Roche Pharmaceuticals